细胞角蛋白19与鳞状细胞癌抗原联合检测在宫颈癌早期筛查及疗效评估中的应用

目的：探讨细胞角蛋白19片段（CYFRA21‐1）与鳞状上皮细胞癌抗原（SCCAg）联合检测在宫颈癌早期诊断、疗效评估中的价值。方法选择2010年8月至2013年8月达州华康医院收治的宫颈癌患者97例，子宫颈上皮非典型增生（CIN ）患者45例，并选择体检的健康妇女50例作为对照组；采用电化学发光免疫分析对CY‐FRA21‐1、SCCAg水平进行检测，比较各组水平。结果与对照组及CIN组相比，宫颈癌患者血清CYFRA21‐1、SCCAg水平显著升高，差异有统计学意义（P＜0．05）；其中宫颈癌Ⅲ～Ⅳ期血清CYFRA21‐1、SCCAg水平及其阳性检出率明显高于Ⅰ～Ⅱ期，组间相比差异具有统计学意义（ P＜0．05）；两者联合检测敏感度升高至62．47％。放化疗后各宫颈癌分期患者血清CYFRA21‐1、SCCAg水平显著降低，与放化疗前相比差异具有统计学意义（P＜0．05）。结论血清CYFRA21‐1、SCCAg检测对宫颈癌早期诊断、疗效评估等方面具有重要的参考价值。

Application of cytokeratin 19 combined with squamous cell carcinoma antigen detection for early diagnosis and curative effect evaluation in patients with cervical cancer

Objective To explore the clinical value of cytokeratin 19 （CYFRA21‐1） combined with squamous cell carcinoma antigen （SCCAg） detection in early diagnosis and curative effect evaluation in patients with cervical cancer. Methods A total of 97 patients with cervical cancer and 45 patients with cervical epithelial atypical hyperpla‐sia（CIN group）in Dazhou Military Hospital from Aug. 2010 to Aug. 2013 were enrolled in this study. Other 50 cases of healthy women ,conducted physical examination ,were enrolled in control group. The levels of CYFRA21‐1 and SC‐CAg were detected by electrochemiluminescence immunoassay method and compared among the three groups. Results Compared with the control and CIN group ,the serum CYFRA21‐1 and SCCAg levels in cervical cancer patients were significantly elevated（P〈0. 05）. The levels and positive detectable rate of serum CYFRA21‐1 and SCCAg were significant higher in stage Ⅲ - Ⅳ of cervical cancer than those in stage Ⅰ - Ⅱ （P〈0. 05）. The sensitivity of com‐bined detection was increased to 62. 47%. The serum CYFRA21‐1 and SCCAg levels were significantly decreased in patients with cervical cancer after chemotherapy ,compared with those before chemotherapy （P〈 0. 05）. Conclusion Combination of serum CYFRA21‐1 and SCCAg detection might be with important reference value for the early diag‐nosis and curative effect evaluation in patients with cervical cancer.